Orphan Drug Lifecycle
What are "orphan drugs" and how their development works.
CRO
Life Science
Regulatory Affairs
Il nostro blog
Analysis of the differences and prospects in the economic and commercial field between Advanced Therapy drugs and traditional drugs
July 14, 2022
Key tools and strategies for the proper marketing of drugs in the countries of the Eurasian Economic Union - EAEU.
July 14, 2022
To simplify the collection of clinical trial data, JSB worked on the development of Counterpoint Software
July 14, 2022
How does the production and supply process change with the advent of Advanced Therapies? The challenges and new scenarios introduced by innovative drugs.
July 14, 2022
The main changes introduced with MDR EU 2017/745: the procedures for obtaining or renewing a certification for Medical Devices.
July 14, 2022
The safety of pesticides: reference standards for drugs of plant origin and other preparations based on medicinal plants
July 14, 2022
For the adaptation to the New Regulations of some Medical Devices, a "Grace Period" is envisaged, a grace period from May 2021 to May 2024.
July 14, 2022
"Orphan" drugs - How and when can a company launch one in Italy? What are the timelines for approval by the competent authorities?
July 14, 2022
The advantages of the new Cold Chain Platform (CCP) for drug monitoring throughout the entire distribution chain.
July 14, 2022
In the first months of 2022, the sixth module of the EUDAMED platform came into force - Further information and general information on the UDI electronic catalog
July 14, 2022